-
1
-
-
34548545280
-
-
Anderson JL, Adams CD. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
-
Anderson JL, Adams CD. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
-
-
-
-
2
-
-
34547789273
-
Drug-induced immune thrombocytopenia
-
Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-587.
-
(2007)
N Engl J Med
, vol.357
, pp. 580-587
-
-
Aster, R.H.1
Bougie, D.W.2
-
3
-
-
0033925843
-
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
-
Sane DC, Damaraju LV, Topol EJ. et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75-83.
-
(2000)
J Am Coll Cardiol
, vol.36
, pp. 75-83
-
-
Sane, D.C.1
Damaraju, L.V.2
Topol, E.J.3
-
4
-
-
33646016570
-
Thromobocytopenia associated with the use of GPIIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors
-
Aster RH, Curtis BR, Bougie DW. et al. Thromobocytopenia associated with the use of GPIIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006;4:678-679.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 678-679
-
-
Aster, R.H.1
Curtis, B.R.2
Bougie, D.W.3
-
5
-
-
0037105428
-
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIA
-
Bougie DW, Wilker PR, Wuitschick ED. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIA. Blood 2002;100:2071-2076.
-
(2002)
Blood
, vol.100
, pp. 2071-2076
-
-
Bougie, D.W.1
Wilker, P.R.2
Wuitschick, E.D.3
-
6
-
-
2242477091
-
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
-
The EPIC Investigators
-
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
-
(1994)
N Engl J Med
, vol.330
, pp. 956-961
-
-
-
7
-
-
31144479574
-
Frequency and management of thrombocytopenia with glycoprotein IIb/IIIa Receptor antagonists
-
Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with glycoprotein IIb/IIIa Receptor antagonists. Am J Cardiol 2006;97:426-429.
-
(2006)
Am J Cardiol
, vol.97
, pp. 426-429
-
-
Huxtable, L.M.1
Tafreshi, M.J.2
Rakkar, A.N.3
-
9
-
-
6344274868
-
Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug
-
Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004;2:985-992.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 985-992
-
-
Curtis, B.R.1
Divgi, A.2
Garritty, M.3
Aster, R.H.4
-
10
-
-
61649100831
-
-
Package insert. ReoPro abciximab, Indianapolis: Eli Lilly, 2002
-
Package insert. ReoPro (abciximab). Indianapolis: Eli Lilly, 2002.
-
-
-
-
11
-
-
0008926519
-
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
-
The PURSUIT Trial Investigators
-
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
-
(1998)
N Engl J Med
, vol.339
, pp. 436-443
-
-
-
12
-
-
0037369974
-
Acute profound thrombocytopenia associated with eptifibatide therapy
-
Nagge J, Jackevicius C, Dzavik V. et al. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-379.
-
(2003)
Pharmacotherapy
, vol.23
, pp. 374-379
-
-
Nagge, J.1
Jackevicius, C.2
Dzavik, V.3
-
13
-
-
33845243141
-
Delayed profound thrombocytopenia associated with eptifibatide
-
Onitilo AA. Delayed profound thrombocytopenia associated with eptifibatide. Am J Hematol 2006;81:984.
-
(2006)
Am J Hematol
, vol.81
, pp. 984
-
-
Onitilo, A.A.1
-
14
-
-
13544250803
-
Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors
-
Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005;127(2 Suppl):53S-59S.
-
(2005)
Chest
, vol.127
, Issue.2 SUPPL.
-
-
Aster, R.H.1
-
15
-
-
0032873921
-
Platelet activation as a potential mechanisim of GP IIb/IIa inhibitor - induced thrombocytopenia
-
Karlheinz P. et al. Platelet activation as a potential mechanisim of GP IIb/IIa inhibitor - induced thrombocytopenia. Am J Cardiol 1999;84:519-524.
-
(1999)
Am J Cardiol
, vol.84
, pp. 519-524
-
-
Karlheinz, P.1
|